While exhibiting its offering in self-administration devices at the CPhI Worldwide event in Frankfurt last week, West told us how patient convenience drives design and development.
Cycle looks to benefit from the advantages of Zydis oral disintegrating tablet technology, developed by Catalent, for four of its drug products treating rare diseases.
Eversana boosts its logistics offering by opening its fourth storage and distribution center in the US, bringing its total footprint to one million-square-feet.
Research has discovered that bacteria will open holes in their cell wall under certain conditions, potentially leading to a new drug target or greater potency of existing antibiotics.
US FDA approves Noven’s schizophrenia treatment administered through a once-daily transdermal delivery system, able to release the antipsychotic drug for 24 hours.
Through funding by Novo Nordisk and the NIH, researchers from MIT have come up with a microneedle containing capsule able to release drug substance into the bloodstream.
Broad adoption of blockchain technology requires manufacturers to look at their investments in the supply chain, just as they look at R&D, AmerisourceBergen executive says.
N4 Pharma creates DNA and RNA transfection technology using silica nanoparticles with an irregular surface, which traps and protects nucleic acid during its journey to cells.
US FDA approves AstraZeneca’s at-home autoinjector for administration of an add-on treatment for severe asthma, matching the indication of GSK’s rival product, Nucala.
Sobi announces that it will acquire Dova, adding Doptelet to its portfolio of hemophilia treatments, as it looks to further expand indications and diversify its revenue base.
AstraZeneca enters a $270m deal with Cheplapharm to divest seven drugs, in order to reduce its portfolio of ‘mature’ medicines and reinvest in other therapeutic areas.
